ADVANCED NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough cancers: early trial seeks safer, smarter treatment
Disease control Recruiting nowThis early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
Could your own tumor cells fight your lung cancer? new trial explores
Disease control Recruiting nowThis study tests whether specially selected immune cells taken from a patient's own lung tumor can be grown in a lab and then given back to shrink advanced non-small cell lung cancer. About 85 adults aged 18–72 with stage IV or unresectable disease and a tumor that can be safely …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 22:28 UTC
-
New hope for rare lung cancer: targeted pill may outperform standard care
Disease control Recruiting nowThis study tests whether the targeted drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific MET gene change. About 133 adults whose cancer worsened after initial therapy will be randomly assigned to receive te…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
Gentler chemo combo aims to keep older lung cancer patients on treatment longer
Disease control Recruiting nowThis study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New pill takes on hard-to-treat lung cancer in major trial
Disease control Recruiting nowThis phase 3 study tests a new daily pill, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 adults will be randomly assigned to receive either the pill or standard treatment. Th…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy targets advanced lung cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new drug combination (JSKN016 plus other treatments) in 288 adults with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to see how well the treatment shrinks tumors and to check for side effec…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for hard-to-treat lung cancer: targeted combo shows promise
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors or delays cancer growth better than st…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for lung cancer patients: expanded access to targeted pill
Disease control AVAILABLEThis program provides oral sevabertinib to adults with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be well enough to perform daily acti…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy aims to control advanced lung cancer in ALK-positive patients
Disease control Recruiting nowThis phase 2 study tests whether combining the targeted drug lorlatinib with local treatments (like radiation or surgery) can better control advanced ALK-positive non-small cell lung cancer. About 30 people who have not had prior targeted therapy will take lorlatinib for 12 weeks…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New combo therapy aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control Recruiting nowThis study tests a new drug called SHR-A1811 combined with either pyrotinib or SHR-1316 in people with advanced HER2-positive non-small cell lung cancer. The goal is to see if these combinations are safe and can shrink tumors. About 324 adults aged 18-75 with good performance sta…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Could killing lung bacteria boost cancer therapy? new trial launches
Disease control Recruiting nowThis early-phase study tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help control advanced non-small cell lung cancer. About 23 adults whose cancer has returned or spread will receive the combination over six…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New hope for rare lung cancer mutation: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) as a first treatment for people with advanced non-small cell lung cancer that has certain rare gene changes (EGFR PACC mutations). About 480 participants worldwide will be random…
Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC